<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03109652</url>
  </required_header>
  <id_info>
    <org_study_id>SNUBMC_2017001</org_study_id>
    <nct_id>NCT03109652</nct_id>
  </id_info>
  <brief_title>Serial Use of Intravenous and Oral Tranexamic Acid in Primary Total Knee Arthroplasty Patients</brief_title>
  <official_title>Serial Use of Intravenous and Oral Tranexamic Acid in Primary Total Knee Arthroplasty Patients: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The usefulness of tranexamic acid(TXA) to reduce blood loss and transfusion in total knee
      replacement arthroplasty(TKRA) has been demonstrated. However, the optimal does, duration of
      treatment and route of administration of TXA to reduce blood loss while minimizing adverse
      effects remain uncertain. Recently, the serial use of perioperative IV and post-operative
      oral TXA has been shown to significantly reduce transfusion rate without increasing
      thromboembolic complications compared to placebo. The aim of this study is to 1) determine
      the beneficial effect and safety of the serial treatment of IV and oral TXA over IV use alone
      and 2) assess the sufficient length of postoperative use of oral TXA in TKRA patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been demonstrated that tranexamic acid (TXA) reduces the peri-operative blood loss as
      well as the need for transfusion in total knee replacement arthroplasty(TKRA). The
      anti-fibrinolytic effects of TXA have been shown to mainly present in the wound that, in
      previous studies, the use of TXA decreased the blood loss without increasing the risk of
      thromboembolic complications. Nevertheless, the optimal dose, duration of treatment and route
      of administration of TXA to reduce blood loss while minimizing adverse effects remain
      uncertain.

      To use TXA as a pharmacologic alternative to transfusion, optimal regimen should be
      elucidated. Various studies have reported the effect of perioperative use of intravenous or
      topical TXA. Meta-analyses concluded that combined use of intravenous and topical TXA is more
      effective in reducing the blood loss and transfusion rate without increasing the risk of deep
      vein thrombosis or pulmonary embolism compared to the use of either intravenous TXA or
      topical TXA alone. Both intravenous and topical administration was conducted pre or
      intraoperatively or within 6 hours post-operatively mainly due to conceivable risk of
      thromboembolic event when TXA is used continuously after surgery. However, regarding the fact
      that systemic activation of fibrinolysis starts post-operatively in TKRA using tourniquets
      and lasts over 18 hours, the continuous use of TXA after surgery might have additional
      benefit over the single day use. Moreover, the serial use of post-operative oral TXA for 5
      days after perioperative IV TXA use has been shown to significantly reduce transfusion rate
      without increasing thromboembolic complications compared to placebo.

      Therefore, in this study, the investigators aimed to 1) investigate the effect of serial use
      of perioperative IV and post-operative oral TXA in reducing the blood loss and transfusion
      risk compared to single day perioperative use of IV TXA and 2) assess the sufficient length
      of postoperative use of oral TXA in TKRA patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2017</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from preoperative hemoglobin at day 2</measure>
    <time_frame>Preop. day 1 to postop. day 2</time_frame>
    <description>Hemoglobin (g/dL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from preoperative hemoglobin at day 6</measure>
    <time_frame>Preop. day 1 to postop. day 6</time_frame>
    <description>Hemoglobin (g/dL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transfusion rate and amount</measure>
    <time_frame>Postoperative day 0 to day 6</time_frame>
    <description>transfusion trigger: packed red blood cell(RBC) 1 pack is given if Hb &lt; 7 or 7 â‰¤ Hb&lt; 8 with symptom of anemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>up to 6 week after operation</time_frame>
    <description>CT angiography on postoperative day 6 for evaluation of deep vein thrombosis, Pulmonary embolism, superficial or deep infection, and other complications are assessed clinically.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculated Blood loss</measure>
    <time_frame>Postop. day 6</time_frame>
    <description>Based on predicted blood volume and hemoglobin balance</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>IV TXA alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One ampule of 500mg/ml tranexamic acid(TXA) inj is injected intravenously during operation after box cutting procedure(before tourniquet deflation). Additionally, 1 ampule of TXA is administrated 3 hours after first injection on the day of operation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV TXA and Oral TXA 5 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One ampule of 500mg/ml tranexamic acid(TXA) inj is injected intravenously during operation after box cutting procedure(before tourniquet deflation). Additionally, 1 ampule of TXA is administrated 3 hours after first injection on the day of operation.
Two 250mg capsules of oral TXA(Transamin Cap) is given three times a day, 30 minutes after each meal, from postoperative day 1 to day 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV TXA and Oral TXA 2 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One ampule of 500mg/ml tranexamic acid(TXA) inj is injected intravenously during operation after box cutting procedure(before tourniquet deflation). Additionally, 1 ampule of TXA is administrated 3 hours after first injection on the day of operation.
Two 250mg capsules of oral TXA(Transamin Cap) is given three times a day, 30 minutes after each meal, from postoperative day 1 to day 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>On the day of operation, same dose of IV tranexamic acid(TXA) is given to all subjects in three study groups. Oral TXA is given from postoperative day 1 only to experimental groups. Duration of oral TXA administration is different between two experimental groups. (5 days in &quot;IV TXA and Oral TXA 5 days group&quot; and 2 days in &quot;IV TXA and Oral TXA 2 days group&quot;)</description>
    <arm_group_label>IV TXA alone</arm_group_label>
    <arm_group_label>IV TXA and Oral TXA 5 days</arm_group_label>
    <arm_group_label>IV TXA and Oral TXA 2 days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Candidate for total knee replacement arthroplasty due to osteoarthritis of the knee.

        Exclusion Criteria:

          -  Known allergic reaction to tranexamic acid

          -  Secondary arthritis (ex. Rheumatic arthritis, traumatic arthritis, septic arthritis)

          -  History of thromboembolic event including deep vein thrombosis, pulmonary embolism,
             cerebral infarction, transient ischemic attack, myocardial infarction, angina

          -  Premenopausal female

          -  Known congenital or acquired coagulopathy

          -  Currently in treatment with Adenosine disphosphate receptor inhibitors, Vitamin K
             antagonist, Factor Xa inhibitor, Direct thrombin inhibitor or Heparin

          -  Aspirin administration within 5 days before operation

          -  Preoperative Prothrombin time(PT) international normalized ratio(INR) &gt; 1.4

          -  Severe systemic comorbidities of American Society of Anesthesiology (ASA) grade 4
             including heart failure, renal failure, hepatic failure, pulmonary disease and cancer

          -  Do not agree to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung-Baik Kang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SMG-SNU Boramae Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seung-Baik Kang, MD, PhD</last_name>
    <phone>+82-870-3931</phone>
    <email>ossbkang@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chan Yoon, MD</last_name>
    <phone>+82-870-2316</phone>
    <email>yoon.chan.alex@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Dongjak gu</state>
        <zip>07061</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung-Baik Kang, MD, PhD</last_name>
      <phone>+82-2-870-3931</phone>
      <email>ossbkang@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Chan Yoon, MD</last_name>
      <phone>+82-2-870-2316</phone>
      <email>yoon.chan.alex@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Seung-Baik Kang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chong Bum Chang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Moon Jong Chang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chan Yoon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Min Kyu Song, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jae-Hoon Shin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Alshryda S, Sarda P, Sukeik M, Nargol A, Blenkinsopp J, Mason JM. Tranexamic acid in total knee replacement: a systematic review and meta-analysis. J Bone Joint Surg Br. 2011 Dec;93(12):1577-85. doi: 10.1302/0301-620X.93B12.26989. Review.</citation>
    <PMID>22161917</PMID>
  </reference>
  <reference>
    <citation>Wang H, Shen B, Zeng Y. Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials. Knee. 2014 Dec;21(6):987-93. doi: 10.1016/j.knee.2014.09.010. Epub 2014 Oct 23. Review.</citation>
    <PMID>25450009</PMID>
  </reference>
  <reference>
    <citation>Wu Q, Zhang HA, Liu SL, Meng T, Zhou X, Wang P. Is tranexamic acid clinically effective and safe to prevent blood loss in total knee arthroplasty? A meta-analysis of 34 randomized controlled trials. Eur J Orthop Surg Traumatol. 2015 Apr;25(3):525-41. doi: 10.1007/s00590-014-1568-z. Epub 2014 Nov 28. Review.</citation>
    <PMID>25430635</PMID>
  </reference>
  <reference>
    <citation>Irwin A, Khan SK, Jameson SS, Tate RC, Copeland C, Reed MR. Oral versus intravenous tranexamic acid in enhanced-recovery primary total hip and knee replacement: results of 3000 procedures. Bone Joint J. 2013 Nov;95-B(11):1556-61. doi: 10.1302/0301-620X.95B11.31055.</citation>
    <PMID>24151279</PMID>
  </reference>
  <reference>
    <citation>Lin C, Qi Y, Jie L, Li HB, Zhao XC, Qin L, Jiang XQ, Zhang ZH, Ma L. Is combined topical with intravenous tranexamic acid superior than topical, intravenous tranexamic acid alone and control groups for blood loss controlling after total knee arthroplasty: A meta-analysis. Medicine (Baltimore). 2016 Dec;95(51):e5344. doi: 10.1097/MD.0000000000005344. Review.</citation>
    <PMID>28002321</PMID>
  </reference>
  <reference>
    <citation>Li JF, Li H, Zhao H, Wang J, Liu S, Song Y, Wu HF. Combined use of intravenous and topical versus intravenous tranexamic acid in primary total knee and hip arthroplasty: a meta-analysis of randomised controlled trials. J Orthop Surg Res. 2017 Feb 2;12(1):22. doi: 10.1186/s13018-017-0520-4.</citation>
    <PMID>28153031</PMID>
  </reference>
  <reference>
    <citation>Cankaya D, Dasar U, Satilmis AB, Basaran SH, Akkaya M, Bozkurt M. The combined use of oral and topical tranexamic acid is a safe, efficient and low-cost method in reducing blood loss and transfusion rates in total knee arthroplasty. J Orthop Surg (Hong Kong). 2017 Jan;25(1):2309499016684725. doi: 10.1177/2309499016684725.</citation>
    <PMID>28176599</PMID>
  </reference>
  <reference>
    <citation>Charoencholvanich K, Siriwattanasakul P. Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial. Clin Orthop Relat Res. 2011 Oct;469(10):2874-80. doi: 10.1007/s11999-011-1874-2. Epub 2011 Apr 22.</citation>
    <PMID>21512813</PMID>
  </reference>
  <reference>
    <citation>Benoni G, Lethagen S, Fredin H. The effect of tranexamic acid on local and plasma fibrinolysis during total knee arthroplasty. Thromb Res. 1997 Feb 1;85(3):195-206. Erratum in: hromb Res 1997 Oct 15;88(2):251.</citation>
    <PMID>9058494</PMID>
  </reference>
  <reference>
    <citation>BlaniÃ© A, Bellamy L, Rhayem Y, Flaujac C, Samama CM, Fontenay M, Rosencher N. Duration of postoperative fibrinolysis after total hip or knee replacement: a laboratory follow-up study. Thromb Res. 2013 Jan;131(1):e6-e11. doi: 10.1016/j.thromres.2012.11.006. Epub 2012 Nov 26.</citation>
    <PMID>23195143</PMID>
  </reference>
  <reference>
    <citation>ReikerÃ¥s O, Clementsen T. Time course of thrombosis and fibrinolysis in total knee arthroplasty with tourniquet application. Local versus systemic activations. J Thromb Thrombolysis. 2009 Nov;28(4):425-8. doi: 10.1007/s11239-008-0299-6. Epub 2008 Dec 6.</citation>
    <PMID>19067121</PMID>
  </reference>
  <reference>
    <citation>Pilbrant A, Schannong M, Vessman J. Pharmacokinetics and bioavailability of tranexamic acid. Eur J Clin Pharmacol. 1981;20(1):65-72.</citation>
    <PMID>7308275</PMID>
  </reference>
  <reference>
    <citation>Nielsen CS, Jans Ã˜, Ã˜rsnes T, Foss NB, Troelsen A, Husted H. Combined Intra-Articular and Intravenous Tranexamic Acid Reduces Blood Loss in Total Knee Arthroplasty: A Randomized, Double-Blind, Placebo-Controlled Trial. J Bone Joint Surg Am. 2016 May 18;98(10):835-41. doi: 10.2106/JBJS.15.00810.</citation>
    <PMID>27194493</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2017</study_first_submitted>
  <study_first_submitted_qc>April 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2017</study_first_posted>
  <last_update_submitted>July 10, 2017</last_update_submitted>
  <last_update_submitted_qc>July 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Seung-Baik Kang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>total knee replacement arthroplasty</keyword>
  <keyword>total knee arthroplasty</keyword>
  <keyword>tranexamic acid</keyword>
  <keyword>oral tranexamic acid</keyword>
  <keyword>transfusion</keyword>
  <keyword>blood loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

